Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Renal Disorder Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Kir4.1/KCNJ10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNJ10 (Kir4.1) Recombinant Protein (Extracellular Loop / Partial) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View KCNJ10 Products |
| Gene Delivery | KCNJ10 Promise-ORF / Lentivirus Premade Particles Full-length human KCNJ10 ORF for stable cell line construction. |
View KCNJ10 Products |
| Benchmark Ab | Anti-KCNJ10 Recombinant Antibody Recombinant positive control for expression and localization verification. |
View KCNJ10 Products |
| Validator | KCNJ10 siRNA Set For knockdown verification in functional assays. |
View KCNJ10 Products |
| Related Target A | KCNJ16 (Kir5.1) Forms functional heterotetramers with Kir4.1 in renal tubule and brain; essential for selectivity counter-screening. |
View KCNJ16 Products |
| Related Target B | AQP4 (Aquaporin-4) Co-localizes with Kir4.1 in astrocytic endfeet; critical for spatial potassium buffering and blood-brain barrier integrity. |
View AQP4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | Lentivirus Premade Particles for stable host cell expression, preserving native tetrameric ion channel conformation. |
| Subfamily Counter-screening (Selectivity vs. Kir channels) | Complete panel of related Kir family targets (including KCNJ16) available for off-target profiling. |
| Lack of Controls | Sequence-verified benchmark antibodies and control lentivirus included. |
| False Positives | Validated siRNA sets included for target knockdown specificity validation. |
Live Kir4.1/KCNJ10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Kir4.1/KCNJ10 therapeutics is intensifying, with major players shifting focus from traditional small-molecule modulators to targeted gene therapies and cell-specific delivery systems. As first-generation therapies for rare channelopathies (such as EAST/SeSAME syndrome) reach preclinical milestones, the next wave of R&D is targeting broader indications including neuropathic pain, epilepsy, and glioblastoma. Maintaining the native tetrameric state of this potassium channel in cellular systems remains the primary bottleneck for high-throughput screening campaigns.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Academic Consortia, Biotech Startups | Epilepsy, EAST Syndrome, Neuropathic Pain | High-throughput Thallium/Potassium Flux Assay (Need Lentivirus for Stable Cell Line) |
| Gene Therapy (AAV/Lentivirus) | Gene Therapy Developers | KCNJ10-deficient Channelopathies | Expression Validation & Function Restoration (Need Sequence-verified ORF & Antibodies) |
| Small Molecule Inhibitors | Oncology Biopharma | Glioblastoma, Astrocytoma | Proliferation & Migration Assays (Need Validated siRNA & Knockdown Tools) |